6/25/2025

Source: SeekingAlpha

6/23/2025

If you buy and hold a stock for many years, you'd hope to be making a profit. Better yet, you'd like to see the share...

Source: Yahoo

6/18/2025

H.C. Wainwright analyst Douglas Tsao says that while a takeover of Sage Therapeutics (SAGE) comes as no surprise, but a deal with Supernus (SUPN) is unexpected, and “leaves open the door for additional competition.” The merger agreement includes a “modest” breakup fee of just $22.4M payable to Supernus in the event Sage accepts a superior offer, the analyst tells investors in a research note. The firm believes the “relatively modest breakup fee” would not dissuade Biogen (BIIB) from pursuing a b

Source: Yahoo

6/17/2025

SUPN inks deal to acquire Sage Therapeutics for up to $795 million, securing rights to depression drug Zurzuvae.

Source: Yahoo

6/17/2025

Sage Therapeutics (SAGE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Source: Yahoo

6/17/2025

Stock market futures are up slightly. Enthusiasm has been tempered by geopolitical risks and uncertainty ahead of Wednesday’s Federal Reserve decision. The Fed is widely expected to hold rates steady, but investors are laser-focused on Chair Powell’s language regarding potential rate cuts later this year. Currently, markets are pricing in a roughly 56% chance of a quarter-point cut by September. In the background, rising tensions between Israel and Iran continue to cast a long shadow. Oil prices

Source: Yahoo

6/16/2025

NEW YORK, June 16, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Sage Therapeutics, Inc. and its board of directors concerning the proposed acquisition...

Source: Finnhub

6/16/2025

The following bids, mergers,acquisitions and disposals were reported by 1330 GMT on Monday: ** Justin Sun's crypto platform, Tron, has reached a dealwith Nasdaq-listed...

Source: Finnhub

6/16/2025

After Biogen failed with a takeover bid in January, Supernus has swooped in to acquire the postpartum depression pill developer.

Source: Yahoo

6/16/2025

Supernus Pharmaceuticals agreed Monday to buy beleaguered biotech Sage Therapeutics in a deal that bolsters its nonpsychiatric portfolio.

Source: Yahoo

6/16/2025

Supernus Pharmaceuticals (SUPN) acquires Sage Therapeutics (SAGE), enhancing its CNS portfolio with Zurzuvae's potential. Read my analysis on this acquisition.

Source: SeekingAlpha

6/16/2025

Health care stocks were flat to higher premarket Monday with the Health Care Select Sector SPDR Fund

Source: Yahoo

6/16/2025

In what one analyst described as an “unremarkable” outcome, the brain drug developer is being acquired for just $8.50 per share, plus non-guaranteed additional payouts, after a series of stumbles that depressed its stock price.

Source: Yahoo

6/16/2025

Supernus Pharmaceuticals signed a definitive agreement to acquire fellow biopharmaceutical company Sage Therapeutics for $8.50 a share in a deal worth an initial $561 million. Sage stock closed last Friday at $6.60 a share, and was up 36% to $9.13 in premarket trading Monday after the deal was announced. The main draw of the deal for Supernus is Sage’s drug Zurzuvae, the first and only oral medication approved by the Food and Drug Administration for treatment of postpartum depression.

Source: Yahoo

6/16/2025

Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (C

Source: Yahoo

6/13/2025

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

Source: Yahoo

6/10/2025

Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it effectively, leading to missed opportunities.

Source: Yahoo

6/6/2025

As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the branded pharmaceuticals industry, including Collegium Pharmaceutical (NASDAQ:COLL) and its peers.

Source: Yahoo

6/2/2025

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer (NYSE:PFE) and its peers.

Source: Yahoo

5/29/2025

New video series explores the impact of ADHD on relationships and the role of Qelbree in helping Jay’s ADHD symptom managementROCKVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals is expanding its partnership with TV personality and sports reporter Jay Glazer in a new content series featuring his wife, Rosie Glazer. The series, which launches its first episode on the All About ADHD YouTube channel in May for Mental Health Awareness Month, offers an intimate look at how ADHD i

Source: Yahoo